Who
Michael F. Cola
Director
Company insider
Files Form 4 as: Director, Phathom Pharmaceuticals; Director, Sage Therapeutics; Chief Executive Officer, Avalo Therapeutics; Chief Executive Officer, Aevi Genomic Medicine; Director, Vanda Pharmaceuticals; Director, Nupathe; Director, Clarient.
In numbers
- Trades disclosed
- 113
- Buys
- 7
- Sells
- 0
- Bought
- $1.6M
- Sold
- $0
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 11 Apr 2006
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —21,500 | filing |
| 11 Jun 2025filed 13 Jun 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —21,500 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 10 Jun 2024filed 11 Jun 2024 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 15 Jun 2023filed 16 Jun 2023 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 16 Jun 2022filed 17 Jun 2022 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —9,947 at $0.00 | filing |
| 25 May 2022filed 27 May 2022 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Oct 2021filed 4 Oct 2021 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,116 at $0.00 | filing |
| 1 Jul 2021filed 2 Jul 2021 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,740 at $0.00 | filing |
| 10 Jun 2021filed 11 Jun 2021 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 21 May 2021filed 24 May 2021 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 1 Apr 2021filed 5 Apr 2021 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,881 at $0.00 | filing |
| 26 Jan 2021filed 28 Jan 2021 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
News
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026PHAT · manilatimes.net · 19 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) versus Praxis Precision Medicines (NASDAQ:PRAX) Financial AnalysisAVTX · tickerreport.com · 16 Oct 2026Avalo Therapeutics (NASDAQ:AVTX) Stock Falls 6.6% – Should You Sell?AVTX · dailypolitical.com · 13 Oct 2026Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsPHAT · dailypolitical.com · 11 Oct 2026Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific MeetingPHAT · manilatimes.net · 8 Oct 2026
0 headlines in the last 90 days name Michael F. Cola; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.